We can’t show the full text here under this license. Use the link below to read it at the source.
Novel plasma biomarkers of amyloid plaque pathology and cortical thickness: Evaluation of the NULISA targeted proteomic platform in an ethnically diverse cohort
New blood markers linked to amyloid plaques and brain thickness in a diverse group using the NULISA protein test
AI simplified
Abstract
Phosphorylated tau-217 (p-tau217) and glial fibrillary acidic protein (GFAP) showed the strongest associations with amyloid beta (Aβ) pathology in plasma samples from an ethnically diverse cohort.
- identified several plasma biomarkers linked to Alzheimer's disease (AD), including p-tau217, GFAP, and p-tau231.
- Markers related to neuroinflammation, such as C-C motif ligand 2 (CCL2), chitotriosidase 1 (CHIT1), and interleukin-8 (CXCL8), were also associated with .
- Astrocytic protein chitinase-3-like protein 1 (CHI3L1) and brain-derived neurotrophic factor (BDNF) were linked to cortical thickness.
- Moderate to strong correlations between NULISA and established immunoassay methods were observed for various biomarkers.
- Plasma biomarker levels may be influenced by factors like age, sex, apolipoprotein E (APOE) genotype, and self-identified race.
AI simplified
Key numbers
108%
Increase in p-tau217 in A+ individuals
Average increase in Aβ PET-positive participants compared to negative controls.
88
Participants in the study
Total number of participants from the Human Connectome Project.
14
Significant associations with
Number of biomarkers significantly associated with Aβ PET status.